Can quantitative monitoring of B cells evaluate the efficacy of Rituximab in primary CNS demyelinating disorders?
Introduction: Rituximab (RTX), initially approved for various blood cancers, is additionally used for the management of primary central nervous system (CNS) demyelinating disorders. This study aimed to quantify the % of B cells following RTX therapy in patients with primary CNS demyelinating disorde...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wolters Kluwer Medknow Publications
2024-01-01
|
| Col·lecció: | Annals of Medical Science and Research |
| Matèries: | |
| Accés en línia: | https://journals.lww.com/10.4103/amsr.amsr_36_23 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|